Chen Alessandra, Ali Nabilah, Boasberg Peter, Ho Allen S
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA.
J Clin Med. 2018 Jan 10;7(1):10. doi: 10.3390/jcm7010010.
Cutaneous squamous cell carcinomas (SCC) affecting the regions of the head and neck can be challenging to resect surgically and refractory to chemotherapy or radiation therapy. Consequently; the treatment of squamous cell carcinomas of the skin is a focus of current research. One such advancement is immunotherapy. Herein we describe clinical remission of invasive, poorly differentiated squamous cell carcinoma of the pre-auricular region with external auditory canal involvement using cetuximab, an epidermal growth factor receptor (EGFR) antibody; and nivolumab, a programmed death receptor-1 (PD-1) antibody. Such durable and comprehensive disease resolution demonstrates the therapeutic potential of cetuximab and nivolumab in surgically challenging, treatment-resistant cutaneous squamous cell carcinoma.
影响头颈部区域的皮肤鳞状细胞癌（SCC）在手术切除方面具有挑战性，并且对化疗或放疗难治。因此，皮肤鳞状细胞癌的治疗是当前研究的重点。免疫疗法就是这样一种进展。在此，我们描述了使用西妥昔单抗（一种表皮生长因子受体（EGFR）抗体）和纳武单抗（一种程序性死亡受体-1（PD-1）抗体），使累及外耳道的耳前区域浸润性、低分化鳞状细胞癌实现临床缓解。这种持久且全面的疾病缓解证明了西妥昔单抗和纳武单抗在手术难度大、治疗耐药的皮肤鳞状细胞癌中的治疗潜力。
